Yaupon Therapeutics Raises $14.4M in Series D Funding

Yaupon Therapeutics, Inc., a Malvern, PA-based specialty pharmaceutical company, has raised $14.4m in Series D funding.

Backers include existing investors Vivo Ventures, Palo Alto Investors and Burrill & Company, and new investor Aperture Venture Partners.

Yaupon Therapeutics is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL), for which it submitted a New Drug Application (NDA) to the FDA.

As stated by Chairman and CEO Steve Tullman, this financing provides the company with the necessary capital to take them through the NDA regulatory review process, while preparing for commercialization either alone or with an industry partner.



Join the discussion